Pharmaceutical Technology - October 2020

PharmTech - Regulatory Sourcebook - October

Issue link: https://www.e-digitaleditions.com/i/1302985

Contents of this Issue

Navigation

Page 70 of 75

Pharmaceutical Technology REGULATORY SOURCEBOOK OCTOBER 2020 71 Manufacturing Under Section 506C of the FD&C Act Guidance for Industry (PDF) • PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (PDF) • Postapproval Changes to Drug Substances Guidance for Industry, Draft Guidance (PDF) • Preparation of Investigational New Drug Products (Human and Animal) (PDF) • Process Validation: General Principles and Practices (PDF) • Providing Regulatory Submissions for Medical Devices in Electronic Format - Submissions Under Section 745A(b) of the Federal Food, Drug, and Cosmetic Act (PDF) • Quality Considerations for Continuous Manufacturing, Draft Guidance (PDF) • Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations (PDF) • Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry (PDF) • Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice (PDF) • Transdermal and Topical Delivery Systems– Product Development and Quality Considerations Guidance for Industry, Draft Guidance (PDF) European Medicines Agency (EMA) EMA Biosimilar Medicines EMA Human Medicines EMA Marketing Authorization EMA Medicines Under Evaluation EMA Post Authorization EMA Research and Development EMA Veterinary Medicines Select EMA Guidance Documents • Advanced Therapies: GCP requirements • Advanced Therapies: GLP requirements • Advanced Therapies: GMP requirements • Biologicals: Active Substance • Biologicals: Finished Product • Good Distribution Practice (GDP) • Good Laboratory Practice (GLP) • Good Manufacturing Practice (GMP) • Biosimilars • Cell Therapy and Tissue Engineering • Gene Therapy • Nanomedicines • Paediatrics • Vaccines • Quality: Active Substance • Quality: Excipients • Quality: Impurities • Quality: Lifecycle Management • Quality: Manufacturing • Quality: Packaging • Quality: Pharmaceutical Development • Quality: Quality by Design • Quality: Specific types of products • Quality: Specifications, Analytical Procedures and Analytical Validation • Quality: Stability Select ICH Guidelines (PDF files) • Q1A(R2) Stability Testing of New Drug Substances and Products • Q1B Stability Testing : Photostability Testing

Articles in this issue

Links on this page

Archives of this issue

view archives of Pharmaceutical Technology - October 2020 - PharmTech - Regulatory Sourcebook - October